Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

Advertisement

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Top News in Prevention: 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content